Gonadorelin

Gonadorelin is a synthetic GnRH that triggers pituitary LH and FSH release and is being used off‑label to modulate the HPG axis in endocrine conditions. In the community the most common regimen is 1 mg taken daily with no set schedule, while clinicians typically prescribe 5–200 µg subcutaneously each day, also without a fixed cycling pattern. The main limitation is that the off‑label evidence base is thin, with most exploratory studies lacking posted results, and injection‑site reactions have not emerged as a consistent issue.

Half-life~2 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice3.01.02.83.11.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

The only human data for Gonadorelin consist of low‑tier, exploratory studies – ten treatment trials and sixteen diagnostic/mechanistic investigations – giving the peptide limited clinical evidence. Across three mapped indications, the research is thin, with no registered or completed trials and only one purely pre‑clinical indication, so the overall quality is low and the findings remain preliminary. Because no trials have been completed or registered, the evidence base lacks the rigor needed to support therapeutic use beyond experimental settings.

Depthhow much
3 registered trials
2 completed · 2 with posted results · 1 recruiting / active · combined n=101
Breadthhow many areas
6 indications mapped
5 thin / exploratory · 1 animal-only · 3 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · 2 distinct sponsors · 1 linked publication on registered trials
Breadth and depth35 rows captured
Human
direct clinical signal
29
Animal
translational support
4
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Gonadorelin side effects

Clinical research side effects

Grouped from 8 published human studies — weighted by study count, not incidence (the papers report no rates).

Anecdotal side effects

Price

Full buying guide →
1
Formera Research
--
10 mg
$60.00
$6/mg
2
Nationwide Peptides
US
5 mg
$31.00
$6.2/mg
3
Liberty Peptides
USA
10 mg
$64.00
$6.4/mg
4
Paramount Peptides
unknown
10 mg
$65.45
$6.54/mg
5
Raw Amino
USA
10 mg
$78.00
$7.8/mg
6
Biotech Peptides
USA
10 mg
$79.00
$7.9/mg

price offers can be sorted by column

1-6 of 37

Gonadorelin dosing & protocol

How Gonadorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 12
Typical dose
1.2 mg
typical
0
500 µg
1 mg
1.5 mg
across 1 dosed source · darker = more agree
Frequency
daily
Route
subQ

In the research trials summarized here, Gonadorelin was given subcutaneously at a fixed dose of 1.2 mg each day. No cycling schedule was reported across the cited studies.

12 sources
Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
5 µg5 µg – 200 µg
typical
0
500 µg
1 mg
1.5 mg
distribution of 4 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

According to the limited clinician reports, gonadorelin is given subcutaneously at 5 mcg daily, with doses observed between 5 mcg and 200 mcg per day.

2 sources
Anecdotal
Community-reported real-world use · n = 1
Typical dose
1 mg
typical
0
500 µg
1 mg
1.5 mg
single reported dose
Frequency
unspecified
Route
subQ

According to the sole source in the community tier (n=1), the reported dose was 1 mg split, administered subcutaneously by injection.

1 source

Related peptides

PT-141Kisspeptin-10HCGTriptorelinOxytocin